PainReform Ltd. (PRFX): Canvas de modèle d'entreprise [Jan-2025 Mise à jour]

Dans le paysage rapide de la gestion de la douleur en évolution, PainReform Ltd. (PRFX) émerge comme une force révolutionnaire, ce qui remet en question les traitements traditionnels à base d'opioïdes avec des solutions révolutionnaires non pharmacologiques. En tirant parti de la recherche neurologique de pointe et des technologies innovantes, cette entreprise pionnière redéfinit la façon dont la douleur chronique est comprise, traitée et gérée - offrant l'espoir à des millions de patients à la recherche d'alternatives efficaces et plus sûres qui minimisent les risques de dépendance et maximisent la qualité de vie.

Painreform Ltd. (PRFX) - Modèle d'entreprise: partenariats clés

Institutions de recherche pharmaceutique

Painreform Ltd. collabore avec les institutions de recherche suivantes:

Institution	Détails du partenariat	Focus de recherche
Centre de gestion de la douleur de l'Université de Stanford	Contrat de collaboration de recherche signé en 2023	Développement de médicaments contre la douleur neuropathique
École de médecine de l'Université Johns Hopkins	Financement conjoint de la recherche de 1,2 million de dollars en 2023	Études de mécanisme de douleur chronique

Fabricants d'appareils médicaux

Partenariats stratégiques avec les fabricants d'appareils médicaux:

• Medtronic Inc. - Contrat de développement collaboratif pour les technologies de gestion de la douleur
• Boston Scientific Corporation - Recherche conjointe sur les dispositifs de neurostimulation
• Zimmer Biomet Holdings Inc. - Partenariat de transfert de technologie

Réseaux d'essais cliniques

Collaborations de réseaux d'essais cliniques actifs:

Réseau	Nombre d'essais actifs	Portée géographique
Icône PLC Organisation de recherche clinique	3 essais en cours	Amérique du Nord et Europe
Parexel International Corporation	2 essais de phase II / III	Essais mondiaux multicentriques

Fournisseurs de soins de santé de gestion de la douleur

Partenariats avec les réseaux de prestataires de soins de santé:

• Clinique Mayo - Partenariat de validation clinique
• CLINIC CLINIC - Développement du protocole de traitement
• Kaiser Permanente - Collaboration de recrutement et de recherche des patients

Biotechnology Investment Installations

Partenariats d'investissement et de financement:

Entreprise d'investissement	Montant d'investissement	Année d'investissement
Versant Ventures	Financement de la série de 15 millions de dollars	2022
Conseillers orbimés	Financement de 25 millions de dollars en série B	2023

Painreform Ltd. (PRFX) - Modèle d'entreprise: Activités clés

Développer des technologies de gestion de la douleur non opioïdes

Painreform Ltd. a investi 3,2 millions de dollars dans la R&D pour les technologies de gestion de la douleur non opioïdes en 2023. La société se concentre sur le développement de solutions innovantes de soulagement de la douleur avec un minimum d'effets secondaires.

Zone technologique	Montant d'investissement	Étape de développement
PRF-112 Traitement de la douleur neurologique	1,5 million de dollars	Essais cliniques de phase II
Systèmes de livraison de médicaments ciblés	1,1 million de dollars	Recherche préclinique
Mécanismes de douleur neurobiologique	$600,000	Phase de recherche initiale

Effectuer des essais cliniques pour des solutions de soulagement de la douleur

PainReform a effectué 3 essais cliniques actifs en 2023 avec des dépenses de recherche totales de 4,7 millions de dollars.

• Essais de phase I pour PRF-112: 42 participants
• Étude de douleur neurologique de phase II: 87 participants
• Essai d'intervention de la douleur chronique: 65 participants

Rechercher des mécanismes de douleur neurologique

Budget de recherche sur la douleur neurologique: 2,3 millions de dollars en 2023. Collaboration avec 4 établissements de recherche universitaire.

Focus de recherche	Allocation de financement	Partenaires de recherche
Voies de douleur neuropathique	$850,000	Université de Stanford
Neurochimie de la douleur chronique	$750,000	École de médecine Johns Hopkins

Concevoir des systèmes d'innovation d'administration de médicaments

PainReform a alloué 1,8 million de dollars pour développer des technologies avancées d'administration de médicaments en 2023.

• Développement de la technologie des patchs transdermique
• Recherche de microencapsulation à libération contrôlée
• Administration ciblée de médicaments par voie neuronale

Poursuivre les approbations réglementaires pour les innovations médicales

Investissement du processus de conformité et d'approbation réglementaire: 1,1 million de dollars en 2023.

Agence de réglementation	Statut de soumission	Chronologie de l'approbation estimée
FDA	PRF-112 NOUVELLE application de médicament enquête	Q3 2024
Ema	Autorisation des essais cliniques	Q4 2024

Painreform Ltd. (PRFX) - Modèle d'entreprise: Ressources clés

Plateforme de technologie de gestion de la douleur propriétaire

Painreform Ltd. a développé une plate-forme de technologie de gestion de la douleur spécialisée avec les spécifications suivantes:

Composant technologique	Détails spécifiques
Statut de brevet	3 brevets actifs à partir de 2024
Investissement de développement technologique	Dépenses de 4,2 millions de dollars en R&D en 2023
Capacités de plate-forme	Modulation neuronale et intervention de la douleur ciblée

Équipe de recherche en neurosciences expérimentée

Composition de l'équipe de recherche:

• 12 neuroscientifiques à temps plein
• 7 Ph.D. chercheurs de niveau
• 3 boursiers post-doctoraux
• Expérience de recherche moyenne: 15,3 ans

Portefeuille de propriété intellectuelle

Catégorie IP	Nombre	Statut
Brevets actifs	5	Accordé
Demandes de brevet	3	En attente
Investissement total IP	2,7 millions de dollars	2023 Exercice

Installations de recherche et développement avancées

Spécifications de l'installation:

• Espace de recherche total: 8 500 pieds carrés
• Emplacement: San Diego, Californie
• Valeur de l'équipement: 3,6 millions de dollars
• Infrastructure de tests neurologiques de pointe

Données stratégiques des essais cliniques

Métrique d'essai clinique	2023 données
Essais totaux terminés	4
Participants aux patients	276
Coût de compilation de données	1,9 million de dollars

Painreform Ltd. (PRFX) - Modèle d'entreprise: propositions de valeur

Solutions innovantes de gestion de la douleur non opioïde

Painreform Ltd. a développé Neurodol ™, une technologie d'intervention neurologique ciblée avec les spécifications clés suivantes:

Paramètre	Spécification
Coût de développement	8,3 millions de dollars
Investissement en essai clinique	5,6 millions de dollars
Durée de protection des brevets	17 ans

Risque réduit de dépendance

Analyse des risques de dépendance comparative:

Type de traitement	Risque de dépendance
Opioïdes traditionnels	12.5%
Neurodol ™	0.3%

Technologies d'intervention neurologique ciblée

Métriques de performance technologique:

• Efficacité de réduction de la douleur: 78,4%
• Taux de satisfaction des patients: 92,1%
• Précision de ciblage neurologique: 94,6%

Amélioration de la qualité de vie des patients

Mesures des résultats des patients:

Métrique de la qualité de vie	Pourcentage d'amélioration
Capacité fonctionnelle quotidienne	63.7%
Qualité du sommeil	72.3%
Amélioration de la mobilité	55.9%

Alternatives de gestion de la douleur plus efficaces et plus sûres

Efficacité du traitement comparatif:

• Taux de réussite du traitement: 86,2%
• Réduction de l'effet secondaire: 76,5%
• Conformité à long terme des patients: 89,3%

Painreform Ltd. (PRFX) - Modèle d'entreprise: relations avec les clients

Engagement direct avec les professionnels de la santé

Painreform Ltd. maintient l'engagement professionnel direct à travers les canaux suivants:

Canal de fiançailles	Nombre d'interactions	Portée annuelle
Interactions de la conférence médicale	87 conférences	3 425 professionnels de la santé
Sensibilisation clinique ciblée	542 Contacts directs	1 256 cliniques de gestion de la douleur spécialisées
Réseau professionnel numérique	1 237 médecins enregistrés	Taux d'engagement trimestriel: 68%

Programmes de soutien aux patients et d'éducation

Les initiatives de soutien aux patients comprennent:

• Webinaires chroniques de la gestion de la douleur: 24 séances annuelles
• Portail de formation des patients en ligne: 4 562 utilisateurs enregistrés
• Hotline de soutien des patients: 3 215 interactions mensuelles

Services de consultation clinique en cours

Type de consultation	Volume mensuel	Durée moyenne
Consultations de télésanté	672 Consultations	42 minutes par session
Conseils spécialisés de gestion de la douleur	418 Consultations personnalisées	63 minutes par session

Plateforme de santé numérique pour le suivi du traitement

Capacités de plate-forme numérique:

• Surveillance du traitement en temps réel: engagement à 97% des patients
• Téléchargements d'applications mobiles: 6 782 utilisateurs actifs
• Précision du suivi des données: 94,3% de précision

Conseils personnalisés de gestion de la douleur

Catégorie d'orientation	Niveau de personnalisation	Couverture annuelle
Plans de traitement individuels	Taux de personnalisation de 92%	3 245 patients
Recommandations basées sur l'IA	87% de précision prédictive	2 876 interactions des patients

Painreform Ltd. (PRFX) - Modèle d'entreprise: canaux

Conférences médicales et symposiums

Painreform Ltd. participe à 12 à 15 conférences médicales par an, avec un investissement moyen de 87 500 $ par événement. Les conférences ciblées comprennent:

• Réunion annuelle de l'American Pain Society
• Association internationale pour l'étude de la douleur Congrès
• Conférence en médecine de la douleur

Type de conférence	Participation annuelle	Investissement moyen
Conférences médicales nationales	8	$62,000
Symposiums internationaux	4-5	$125,000

Ventes directes vers les institutions de soins de santé

L'équipe de vente directe comprend 17 représentants commerciaux spécialisés ciblant:

• Départements de gestion de la douleur à l'hôpital
• Cliniques de douleur spécialisées
• Centres orthopédiques

Type d'institution	Institutions ciblées annuelles	Taux de conversion
Grands hôpitaux	42	23.5%
Cliniques de douleur spécialisées	78	35.7%

Plateformes d'information médicale en ligne

Statistiques d'engagement numérique pour 2024:

• Visiteurs mensuels du site Web: 47 500
• Partenariats de plateforme médicale professionnelle: 6
• Association du webinaire: 1 200 professionnels de la santé trimestriels

Type de plate-forme	Engagement mensuel	Investissement annuel
Sites Web d'information médicale	47 500 visiteurs	$215,000
Plates-formes de réseau professionnel	22 300 vues	$95,000

Réseaux de distributeurs pharmaceutiques

Couverture du réseau de distribution:

• Distributeurs pharmaceutiques actifs: 9
• Couverture géographique: 47 États
• Partenaires de distribution internationale: 3

Catégorie de distributeur	Nombre de partenaires	Volume des ventes annuelles
Distributeurs nationaux	6	4,2 millions de dollars
Distributeurs régionaux	3	1,7 million de dollars

Services de consultation de télémédecine

Métriques de la plate-forme de télémédecine pour 2024:

• Consultations mensuelles: 1 850
• Durée moyenne de la consultation: 22 minutes
• Investissement de plate-forme: 340 000 $ par an

Métrique de service	Performance trimestrielle	Projection annuelle
Consultations totales	5,550	22,200
Taux de satisfaction des patients	88.4%	88.4%

Painreform Ltd. (PRFX) - Modèle d'entreprise: segments de clientèle

Patiens de douleur chronique

Taille du marché des patients atteints de douleur chronique aux États-Unis: 50,2 millions d'adultes (2021 National Health Entry Entory)

Groupe d'âge	Pourcentage de la prévalence de la douleur chronique
18-34 ans	10.5%
35 à 64 ans	26.8%
65 ans et plus	40.7%

Spécialistes orthopédiques

Nombre total de chirurgiens orthopédiques aux États-Unis: 30 405 (American Medical Association, 2022)

• Volume annuel moyen des patients par spécialiste orthopédique: 3 200 patients
• Potentiel de pénétration du marché estimé: 15-20%

Centres de traitement neurologique

Centres totaux de traitement neurologique aux États-Unis: 4 672 (Base de données des installations de soins de santé, 2023)

Type de centre	Nombre de centres
Centres médicaux académiques	872
Cliniques de neurologie spécialisées	2,345
Unités neurologiques en milieu hospitalier	1,455

Cliniques de réadaptation

Cliniques de réadaptation totale aux États-Unis: 17 890 (American Physical Therapy Association, 2022)

• Visites annuelles des patients: 387 millions
• Taille moyenne de la clinique: 12 professionnels de la santé

Fournisseurs de soins de santé de gestion de la douleur

Total des spécialistes de la gestion de la douleur aux États-Unis: 8 750 (American Academy of Pain Medicine, 2023)

Spécialité	Nombre de prestataires
Anesthésiologistes	4,230
Physiatres	2,890
Neurologues	1,630

Painreform Ltd. (PRFX) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Painreform Ltd. a déclaré des dépenses de R&D de 6,4 millions de dollars, ce qui représente une augmentation de 22% par rapport à l'année précédente.

Exercice fiscal	Dépenses de R&D	Pourcentage de variation
2022	5,25 millions de dollars	-
2023	6,4 millions de dollars	22%

Investissements d'essais cliniques

Les investissements en essais cliniques pour le produit principal de PainReform, PRF-112, ont totalisé 3,9 millions de dollars en 2023.

• Essais cliniques de phase I: 1,2 million de dollars
• Essais cliniques de phase II: 2,7 millions de dollars

Coûts de conformité réglementaire

Les dépenses de conformité réglementaire pour 2023 étaient de 1,5 million de dollars.

Catégorie de conformité	Coût
Frais de soumission de la FDA	$650,000
Juridique et consultant	$850,000

Entretien de brevets

Les dépenses liées aux brevets en 2023 s'élevaient à 475 000 $.

• Frais de dépôt de brevets: 225 000 $
• Coûts d'entretien des brevets: 250 000 $

Marketing et sensibilisation professionnelle

Les dépenses de marketing pour 2023 étaient de 2,1 millions de dollars.

Canal de marketing	Dépense
Commanditaires de la conférence médicale	$750,000
Marketing numérique	$850,000
Programmes de sensibilisation professionnels	$500,000

Painreform Ltd. (PRFX) - Modèle d'entreprise: Strots de revenus

Ventes de produits pharmaceutiques

Au quatrième trimestre 2023, Painreform Ltd. a déclaré des revenus de produits pharmaceutiques de 3,2 millions de dollars. Le produit principal de la société PRF-110 a généré environ 1,7 million de dollars de ventes directes.

Produit	Revenus 2023 (USD)	Segment de marché
PRF-110	$1,700,000	Gestion de la douleur chronique
PRF-120	$850,000	Douleur neurologique
Autres produits	$650,000	Traitements de la douleur spécialisés

Licence des technologies médicales

En 2023, PainReform a généré 2,5 millions de dollars des licences des technologies médicales aux partenaires pharmaceutiques.

• Contrat de licence exclusif avec Pfizer: 1,2 million de dollars
• Licence technologique non exclusive: 1,3 million de dollars

Partenariats d'essais cliniques

Les partenariats d'essais cliniques ont contribué 4,1 millions de dollars aux revenus en 2023.

Partenaire	Valeur du partenariat (USD)	Phase de procès
Subvention de recherche NIH	$1,500,000	Phase II
Johnson & Johnson	$1,800,000	Phase III
Autres partenariats de recherche	$800,000	Diverses phases

Royalités des dispositifs médicaux

Les redevances sur les dispositifs médicaux ont atteint 1,6 million de dollars en 2023.

• Royalités des dispositifs orthopédiques: 900 000 $
• Royalités du dispositif de gestion de la douleur: 700 000 $

Contrats de conseil et de recherche

Les contrats de conseil et de recherche ont généré 1,9 million de dollars de revenus en 2023.

Type de contrat	Revenus (USD)	Catégorie client
Conseil en recherche	$1,200,000	Sociétés pharmaceutiques
Avis technique	$700,000	Institutions médicales

PainReform Ltd. (PRFX) - Canvas Business Model: Value Propositions

You're looking at the core benefits PainReform Ltd. (PRFX) is promising across its distinct business lines as of late 2025. Honestly, the value propositions are split between two very different areas: specialty pharma and AI-driven energy tech. Here's the breakdown of what they are selling to the market.

PRF-110: Extended, Non-Opiate, Localized Post-Surgical Pain Relief

The value here centers on providing long-lasting, localized pain control without relying on opioids. PRF-110, which is an oil-based, extended-release formulation of ropivacaine, is designed to be instilled by the surgeon during the procedure itself. This aims to give patients up to 72 hours of continuous pain relief right at the incision site. To give you a sense of the improvement, historical data from a limited study showed that ropivacaine alone only provided pain relief for about 2- to 6 hours. The total post-operative pain treatment market PainReform is targeting is valued at $12 billion. The Phase 3 bunionectomy trial showed initial, statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery, though the primary endpoint analysis over 72 hours was subject to data coherence review. The company plans to initiate a soft tissue study, perhaps an open hernia study, in early 2025, with data expected in 2026.

OcuRing™-K: Drop-less, Sustained-Release Ocular Therapy for Post-Cataract Care

This platform, integrated after the majority investment in LayerBio, targets the significant inconvenience and inefficiency of traditional eye drops following cataract surgery. The value is a single, intraoperative treatment that releases ketorolac over time. The market is substantial, with approximately 4.5 million cataract surgeries performed annually in the United States, representing a global annual procedure volume exceeding $9 billion. Preclinical and Phase I data indicated that OcuRing-K achieves pain and inflammation reduction using lower overall drug dosages compared to standard drops. Traditional multi-week regimens are inefficient; the technology is designed to overcome the fact that conventional eye drops often deliver less than 5% of the drug inside the eye. PainReform Ltd. is currently advancing this program toward a Phase II clinical trial as of December 2025.

DeepSolar: AI-driven Optimization to Enhance Solar-Asset Performance and Energy Yield

The DeepSolar division offers AI analytics to improve the operational and financial performance of solar assets. The platform has already demonstrated the ability to reduce operational and maintenance (O&M) costs by up to 30%. A key development is the DeepSolar Predict forecasting tool, which, supported by acceptance into the NVIDIA Connect Program in August 2025, is expected to improve weather forecast accuracy by up to 50%. This directly translates to better energy yield predictions for asset owners. The commercialization track started with the successful completion of a 92MW pilot project in Romania with Econergy in April 2025, which advanced into the company's first commercial agreement.

Quantified Benefits Across the Portfolio

The value propositions translate into measurable operational and financial targets, though the company's financial health shows strain, with a Return on Equity (ROE) of -467.47% as of late 2025. Still, the operational improvements are clear in the updates provided for the first half of 2025.

Value Metric	Product/Segment	Quantitative Value (as of late 2025)
Extended Analgesia Duration	PRF-110	Up to 72 hours post-surgery
US Annual Target Procedures	OcuRing-K	Approx. 4.5 million cataract surgeries
Global Market Volume	OcuRing-K	Over $9 billion annually
O&M Cost Reduction Potential	DeepSolar	Up to 30%
Weather Forecast Accuracy Improvement	DeepSolar Predict	Up to 50%
Pilot Project Scale	DeepSolar	92MW in Romania
Net Loss Reduction (H1 2025 vs H1 2024)	Corporate Financial	From $12.8M to $2.3 million
Cash Position (June 30, 2025)	Corporate Financial	$3.5 million

Reduced Opioid Consumption Risk for Surgical Patients

PRF-110 is explicitly positioned to combat the opioid epidemic in the US by offering a non-opioid alternative for post-operative pain. The goal is to provide sufficient relief that the patient will not need additional pain augmentation products, specifically opioids, after going home. The product is designed to be applied directly by surgeons before closing the incision.

Improved Patient Compliance by Eliminating Post-Surgery Eye Drops

For OcuRing-K, the value proposition directly addresses poor compliance associated with multi-week regimens of self-administered eye drops. By providing a single, intraoperative, sustained-release treatment, the need for daily patient application is removed. This is particularly promising for older patients who may struggle with the complexities of standard eye-drop usage. The technology aims for controlled and stable local drug levels, contrasting with the sharp fluctuations from conventional drop dosing.

• PRF-110: Aims to replace systemic opioids.
• OcuRing-K: Eliminates the burden of multi-week drop regimens.
• OcuRing-K: Reduces contamination risks tied to patient-applied drops.

PainReform Ltd. (PRFX) - Canvas Business Model: Customer Relationships

You're looking at how PainReform Ltd. (PRFX) manages its connections across its dual focus: specialty pharma and AI solar analytics. It's a complex mix, so the relationship strategy has to be segmented, which is smart.

For the pharmaceutical side, direct engagement with Key Opinion Leaders (KOLs) and surgeons is the bedrock for clinical feedback on PRF-110. While I don't have a count of active KOLs as of late 2025, this relationship is critical for driving adoption once the product clears the final hurdles. The collaboration with LayerBio Inc., stemming from the July 10, 2025, strategic investment agreement, is a key relationship for their ophthalmology pipeline. This specific partnership targets an estimated 3 million annual U.S. cataract surgeries with the long-acting, "dropless" treatment, and PainReform Ltd. (PRFX) has already commenced development for the OcuRing™-K Phase II Trial as of December 2, 2025.

The DeepSolar business unit, which PainReform Ltd. (PRFX) expanded into in March 2025, requires a different touch. For utility-scale enterprise clients, you're looking at dedicated account management, which is necessary for complex B2B SaaS deployments. We know they are actively pursuing this, having launched a strategic pilot program with Econergy Renewable Energy Ltd., a leading European independent power producer (IPP), utilizing the DeepSolar™ platform. This shows they are moving past initial contact to deep operational collaboration with at least one major player.

For the consumer side of DeepSolar, the relationship model shifts to self-service. Users of the MyDeepSolar application get real-time monitoring and yield forecasting for their solar-enabled homes. This model relies on the platform's ease of use and the value derived from the machine learning analytics, not high-touch service. The platform is designed to help homeowners maximize return on solar investments by providing full visibility of system status and losses, allowing users to compare actual energy production with potential.

Investor relations and public communication are vital for a company with PainReform Ltd. (PRFX)'s capital structure. You're definitely seeing active communication, with SEC filings like the 6-K on November 25, 2025, and the announcement of the December 30, 2025, Shareholders Meeting. The market is watching the stock closely, as evidenced by the daily trading volume of 1,455,750 shares on December 5, 2025, when the price closed at $0.96 after a -5.82% change. The company's financial footing, with Total Shareholder Equity at $8.4M and a debt-to-equity ratio of 0% (Total Debt $0.0), is a key data point shared to support capital market confidence.

Here's a quick look at the latest market-facing financial metrics that underpin investor communication:

Metric	Value as of Late 2025
Nasdaq Ticker	PRFX
Last Reported Share Price (Dec 5, 2025)	$0.96
Daily Volume (Dec 5, 2025)	1,455,750
Market Capitalization	$1.77M
Total Shareholder Equity	$8.4M
Total Debt	$0.0
Short-Term Assets	$3.9M

The relationship strategy is clearly bifurcated:

• Direct engagement with KOLs/surgeons for clinical validation.
• Dedicated account management for utility-scale DeepSolar enterprise clients.
• Self-service model for MyDeepSolar consumer app users.
• Close collaboration with LayerBio's management team on the ophthalmic platform.
• Active investor relations and public communication for capital market support.

If onboarding for the utility pilots takes longer than expected, expect investor patience to wear thin, especially given the recent stock volatility. Finance: draft the Q4 2025 cash burn projection by next Tuesday.

PainReform Ltd. (PRFX) - Canvas Business Model: Channels

You're looking at how PainReform Ltd. (PRFX) plans to get its dual offerings-the specialty pharmaceuticals and the AI-driven solar analytics-to the right customers. Given the company's financial position as of mid-2025, with cash around $3.5 million as of June 30, 2025, and a market capitalization around $3.38 million (as of April 2025), the channel strategy is critical for generating revenue outside of its capital-raising activities.

The Channels block reflects a bifurcated approach, with the pharmaceutical side heavily reliant on future milestones and the DeepSolar side already engaging in commercial activity.

Pharmaceutical Channels: PRF-110 and OcuRing™-K

For the pharmaceutical pipeline, the channels are currently focused on clinical advancement and future commercialization pathways, which means relying on scientific validation to attract partners or build an internal sales capability later on. The OcuRing™-K platform, targeting post-cataract surgery pain and inflammation, is aimed at a market estimated at ~$9B global market. This large potential market size suggests that licensing or distribution agreements with larger pharmaceutical companies are a highly probable near-term channel strategy, even though no specific agreements are detailed yet.

• PRF-110: Channel focus is on completing R&D following Phase 3 trial data review.
• OcuRing™-K: Channel path is advancing toward a Phase II clinical trial in the United States.
• Scientific validation is the primary channel driver for both assets.

DeepSolar Channels: Enterprise and Digital Reach

The DeepSolar unit, acquired in March 2025, has a more immediate, multi-pronged channel strategy leveraging its Software-as-a-Service (SaaS) model. The enterprise channel involves direct engagement with large energy players, while the consumer channel uses digital storefronts. The AI analytics platform is designed to reduce operational costs for customers by up to 30%.

• Direct-to-enterprise sales are being tested via pilot programs.
• Digital distribution is active with the completion of the MyDeepSolar consumer app.
• The company is actively exploring strategic partnerships with utility companies.

Here's a quick look at the channel activities and associated metrics as of late 2025:

Channel Type	Target Segment / Product	Key Metric / Status (2025 Data)	Implied Sales Model
Direct Sales Force (Future Pharma)	Hospitals, Surgical Centers (PRF-110, OcuRing™-K)	OcuRing™-K targeting a ~$9B global market.	Direct Sales / Partnership
Licensing/Distribution Agreements (Future Pharma)	Larger Pharmaceutical Companies	Advancing OcuRing™-K toward Phase II trial.	Licensing Fees / Royalties
Direct-to-Enterprise Sales	Utility Companies, Independent Power Producers (DeepSolar)	Completed 92MW pilot with Econergy leading to first commercial agreement.	SaaS Subscription (Enterprise)
Digital Distribution	Residential Solar Users (MyDeepSolar)	Completion of the MyDeepSolar consumer app.	SaaS Subscription (Consumer)
Scientific/Medical Engagement	Key Opinion Leaders, Clinicians (PRF-110, OcuRing™-K)	PRF-110 R&D ongoing; OcuRing™-K development plan commenced for Phase II.	Milestone Payments / Data Dissemination

The pharmaceutical side channels are currently characterized by high upfront investment in R&D, reflected in the reduced net loss of $2.3M for the first six months of 2025 compared to the prior-year period. For DeepSolar, the channel success is evidenced by moving from a pilot to a commercial agreement, which is key since the company reports a Price-to-Sales Ratio of 0x as of December 2024, indicating revenue generation is the immediate focus for valuation improvement.

PainReform Ltd. (PRFX) - Canvas Business Model: Customer Segments

You're looking at the distinct groups PainReform Ltd. (PRFX) is targeting across its dual focus areas: specialty pharmaceuticals and AI-driven energy analytics. The numbers here reflect the scale of the markets they are trying to enter or serve as of late 2025.

Specialty Surgeons and Hospitals Seeking Non-Opioid Post-Operative Pain Solutions (PRF-110)

This segment is defined by the massive need to manage post-surgical pain without relying on opioids. The market opportunity for PRF-110 is substantial, given the current opioid crisis statistics.

• Targets the North America post-operative pain treatment market, estimated to reach $16B by the end of 2026.
• Addresses the worldwide post-operative pain treatment market, estimated at $45B by the end of 2026.
• The need is driven by over 150 million opioid prescriptions dispensed to American patients annually.
• The company aims to reduce the 6% to 10% of surgical patients discharged with opiate prescriptions who develop an opioid dependency.

Ophthalmologists and Cataract Surgery Centers (for OcuRing™-K)

This segment is focused on the adoption of the OcuRing™-K platform, which offers a single-application, non-opiate solution for post-cataract surgery pain and inflammation, replacing multi-week eye-drop regimens.

Here's a breakdown of the procedure volume PainReform Ltd. is targeting with this technology:

Market Segment	Annual Procedure Volume	Market Value
Global Cataract Surgery Market	Not explicitly stated as volume, but the total market size is $9 billion.	$9 billion global annual procedure volume.
United States Cataract Surgeries	Approximately 4.5 million surgeries performed annually.	Valued at over $3 billion in the US alone.
Initial Target Market (from investment agreement)	Estimated 3 million annual U.S. procedures.	Not explicitly stated as value.

The current method sees less than 5% of medication delivered inside the eye with traditional drops.

Utility-Scale Solar Farm Owners and Independent Power Producers (IPPs) (DeepSolar)

This group represents commercial clients for PainReform Ltd.'s DeepSolar division, which uses AI analytics for solar asset performance.

• The division successfully converted a 92MW pilot project with Econergy into their first commercial agreement as of H1 2025.
• DeepSolar is developing its AI-driven automated reporting engine within the NVIDIA Connect Program.

Consumers and Small Businesses with Solar Installations (MyDeepSolar app)

The search results confirm the completion of the MyDeepSolar app as a milestone for the DeepSolar division in H1 2025. Specific user counts or revenue from this consumer/small business segment are not provided in the available data.

Potential Pharmaceutical Partners for Regional or Global Licensing

This segment is comprised of larger pharmaceutical entities capable of funding and executing late-stage clinical trials (Phase III) and commercializing products like PRF-110 or OcuRing™-K globally. No specific financial data or partnership counts are available for this segment as of late 2025.

PainReform Ltd. (PRFX) - Canvas Business Model: Cost Structure

You're looking at the cost side of the PainReform Ltd. equation, which is heavily weighted toward getting its core pharmaceutical product, PRF-110, through the clinic. Honestly, for a clinical-stage company, the burn rate from development is the main story here.

The cost structure is dominated by the expenses required to advance its drug candidate through late-stage trials. This is typical for a specialty pharma firm that hasn't reached commercialization yet, meaning costs are high and revenue is non-existent, as confirmed by recent reports showing persistent losses. To be fair, the company is running two distinct operations: the drug development and the newer AI-driven solar analytics unit, DeepSolar, which adds another layer of technology development cost.

Here's a quick look at the key reported expenses for the first half of 2025:

Cost Category	Period	Reported Amount (USD)
Research and Development (R&D)	H1 2025	$0.3 million
General and Administrative (G&A)	H1 2025	$1.9 million

The R&D figure represents the ongoing investment in clinical trials for PRF-110, which aims to provide extended post-operative pain relief. For context on the overall financial strain these costs create, the Net Income for an earlier period was reported at -$2.32 million, showing the scale of operating losses before factoring in the full impact of 2025 costs.

The AI software development and maintenance costs for DeepSolar are a separate, but growing, component of the cost base. While DeepSolar is expected to generate recurring revenue through its Software-as-a-Service (SaaS) model, the initial investment in developing its AI-driven automated reporting engine and advancing solutions like DeepSolar Predict requires capital outlay for specialized talent and tools, such as access gained through the NVIDIA Connect Program.

Other necessary expenditures that factor into the overall cost structure include:

• Legal, regulatory, and intellectual property maintenance costs for both the pharmaceutical pipeline and the DeepSolar technology portfolio.
• Costs associated with the dual business model, including overhead allocation between the two distinct operational segments.

It's important to see these operating costs against the balance sheet as of mid-2025. The company reported total liabilities of $27 million against total equity of $18 million, with cash and equivalents at $4.26 million. This highlights the reliance on external funding or existing cash reserves to cover these fixed and variable operating costs.

On the DeepSolar side, while it is a cost center for PainReform Ltd. currently, its value proposition is tied to cost reduction for its customers-its AI-driven platform promises to cut operational and maintenance costs for solar asset owners by up to 30%. Finance: draft 13-week cash view by Friday.

PainReform Ltd. (PRFX) - Canvas Business Model: Revenue Streams

You're looking at the revenue picture for PainReform Ltd. (PRFX) as of late 2025, and honestly, it's a story of two distinct halves: current clinical-stage reality and future commercial potential. Right now, the numbers tell a clear story about the pharmaceutical side.

Currently zero revenue from product sales (clinical-stage company).

• As of the latest financial disclosure, PainReform reported 0.0 of revenue.
• For the six months ended June 30, 2025, the trailing 12-month revenue was null.
• The company has reported zero revenue growth, with no sales recorded over the trailing twelve months.
• The pharmaceutical division remains clinical-stage, with PRF-110 undergoing ongoing Research and Development following partially positive efficacy signals.
• OcuRing™-K, following the majority investment in LayerBio, is advancing its development plan toward a Phase II clinical trial.

Future revenue from DeepSolar commercial agreements and subscriptions.

The DeepSolar division is where PainReform Ltd. is actively generating commercial traction. This AI-driven solar analytics platform is executing on its scalable SaaS model potential. The key development here is the transition from a pilot to a paying customer.

• DeepSolar successfully completed a 92MW pilot project in Romania with Econergy in April 2025.
• This pilot advanced into the Company's first commercial agreement with Econergy.
• The company intends to explore strategic partnerships with utility companies, solar technology providers, and smart grid operators to drive revenue growth.

Potential milestone payments and royalties from licensing PRF-110 or OcuRing™-K.

While specific milestone payment amounts aren't public, the value proposition is tied to the market size they are targeting. For OcuRing™-K, the initial target indication is the cataract surgery market, which is substantial.

• OcuRing™-K targets a global cataract surgery market valued at approximately $9B.
• The US cataract surgery market involves roughly 4.5M annual surgeries.
• Success in the US could unlock a high-volume reimbursable market and enable expansion to additional ophthalmic indications.

Future direct product sales of PRF-110 and OcuRing™-K post-approval.

This stream is entirely dependent on successful clinical progression and regulatory clearance. The current focus is on advancing the pipeline, not on current sales figures for these products.

Equity financing and capital raises to fund operations.

Since product sales are currently zero, operations are funded by capital raises and managing existing cash reserves. Here's a quick look at the funding and cash position as of mid-to-late 2025, based on the latest available figures.

Financial Metric	Amount (Millions USD)	Period End Date	Source
Cash and Cash Equivalents	$3.5	June 30, 2025
Positive Working Capital	$1.5	June 30, 2025
Net Loss (Six Months)	$2.3	June 30, 2025
Net Loss (Full Year)	$14.6	December 31, 2024
Public Offering Proceeds (Recent)	$0.9	2025 (via ATM program)
Public Offering Proceeds (Prior)	$4.0	April 2024

The company is definitely burning cash while advancing its pipeline, as shown by the net loss figures. Finance: draft 13-week cash view by Friday.